-
About UsBeijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. -
R&D and ProductsPrimarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases. -
Investor RelationsGuided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
2021
February 3: Subsidiary Huonland wins the national centralized procurement bid for "Olopatadine Hydrochloride."
March 30: The company signed a strategic cooperation agreement with Qingsong Pharmaceutical.
July 28: The company obtained Certificate B of the Pharmaceutical Production License.
August 9: The NL005 project completed enrollment of the last patient in the Phase IIa clinical trial.
September 8: The company’s first CDMO project, “Levofloxacin,” has received the Drug Registration Approval.
October 22: The groundbreaking ceremony for the Intelligent Biopharmaceutical Industry Base was held.
November 9: The company has obtained certification under the three ISO systems: ISO9001, ISO45001, and ISO14001.
November 15: The company listed on the Beijing Stock Exchange.
Share to:
Friendly Links: Baidu | NORTHLAND
Contact Information
Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing
Follow Us
Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.
Web site
NL-BIO
NL003
NL005